Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 5, 2000, Pages 333-345

  Rusckowski, M ^a   Qu, T ^a   Roskey, A ^b   Agrawal, S ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GENE EXPRESSION MODULATOR 231; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TUMOR LEVEL; ENZYME SUBUNIT; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0033757943     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.333     Document Type: Article

References (36)

1. Factors affecting the specificity and mechanisms of action of antisense oligonucleotide
2. Antisense therapeutics: Is it as simple as complementary base recognition?
3. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines
4. Pharmacokinetics of antisense oligonucleotides
5. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioate in mice
6. Pharmacokinetics of oligonucleotides
7. Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in animals. Antisense research and application
8. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
9. Antisense therapeutics
10. Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo
11. Antisense oligonucleotides: Is the glass half full or half empty?
12. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
13. Phase I trial of a second generation oligonucleotide (GEM 231) targeted at type I protein kinase A in patients with refractory solid tumors
14. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
15. Pharmacokinetic properties of several novel analogs in mice
16. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice
17. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
18. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
19. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
20. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion
21. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rats following single injections and continuous infusion
22. A single-injection protein kinase A-directed antisense treatment to inhibit turnout growth
23. Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver
24. Largescale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates
25. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
26. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intervenous administration or continuous subcutaneous infusion to mice
27. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
28. Coadministration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition
29. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide
30. Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioate in mice
31. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and antiepidermal growth factor-receptor antibody on human breast cancer cell growth
32. Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide
33. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
34. In vivo stability, disposition and metabolisms of a 'hybrid' oligonucleotide phosphorothioate in rats
35. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HW-infected subjects
36. Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice